Moderna is paring back gains, but Merck stock remains a buy
Covered by 1 source · 1 article
Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial results. A recent late-stage clinical trial…
Covered by
